メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
東北大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Serum soluble Fas level as a prognostic factor in patients with gynecological malignancies
R. Konno, T. Takano, S. Sato, A. Yajima
大学病院・臨床研究推進センター
研究成果
:
Article
›
査読
68
被引用数 (Scopus)
概要
フィンガープリント
フィンガープリント
「Serum soluble Fas level as a prognostic factor in patients with gynecological malignancies」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Serum
100%
Patient
57%
Krukenberg Tumor
42%
Programmed Cell Death
28%
Endometrium Carcinoma
28%
Uterine Cervix Carcinoma
28%
Female
28%
Cancer
28%
Survival
28%
Carcinoma
14%
Prognostic Factor
14%
Advanced Cancer
14%
Enzyme Linked Immunosorbent Assay
14%
Survival Rate
14%
Proportional Hazards Model
14%
Natural Killer Cell
14%
Cell Surface
14%
Fas Ligand
14%
Radiation Therapy
14%
Malignant Neoplasm
14%
Carcinogenesis
14%
Alternative RNA Splicing
14%
Cervical Cancer
14%
Endometrial Cancer
14%
Serum Group
14%
Nursing and Health Professions
Inpatient
85%
Ovary Carcinoma
42%
Endometrium Carcinoma
28%
Control
28%
Donor
28%
Survival
28%
Uterine Cervix Carcinoma
28%
Advanced Cancer
14%
Proportional Hazards Model
14%
Survival Rate
14%
Malignant Neoplasm
14%
Chemotherapy
14%
Uterine Cervix Cancer
14%
Radiotherapy
14%
Endometrium Cancer
14%
Enzyme Linked Immunosorbent Assay
14%
Carcinoma
14%
Death
14%
Carcinogenesis
14%
Fas Ligand
14%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Carcinoma
42%
Endometrium Carcinoma
28%
Uterine Cervix Carcinoma
28%
Survival
28%
Fas Ligand
14%
Survival Rate
14%
Malignant Neoplasm
14%
Carcinoma
14%
Carcinogenesis
14%
Endometrium Cancer
14%
Uterine Cervix Cancer
14%
Advanced Cancer
14%
Death
14%
Immunology and Microbiology
Apoptosis
28%
Survival
28%
Cell Surface
14%
Fas Ligand
14%
Natural Killer Cell
14%
ELISA
14%
Survival Rate
14%
Alternative RNA Splicing
14%
Serum Group
14%
Biochemistry, Genetics and Molecular Biology
Apoptosis
28%
Survival
28%
Carcinogenesis
14%
Natural Killer Cell
14%
Survival Rate
14%
Alternative Splicing
14%
Fas Ligand
14%
Serum Group
14%